Podcasts

E-Books

Videos

Articles

Business & Practice

Tony Hagen is senior managing editor for The Center for Biosimilars

The strength of a patent wall built up around an originator biologic depends on the quality of patents that make it up and the originator company's willingness to engage in costly litigation. Part 2 of a series.  

Strength of Patent Protection Varies by Patent Type

In this first part of a series, intellectual property attorneys from the Biotechnology Innovation Organization (BIO) contend that originator patents are not the formidable obstacles to biosimilars they are made out to be. 

BIO Attorneys Address Patent Thicket Misconceptions

Alejandro Menchaca is a shareholder at McAndrews, Held and Malloy, a full-service intellectual property law firm. He is also a long-standing adjunct professor in the area of intellectual property law at University of Illinois Chicago School of Law. He can be reached at 

The Biologics Price Competition and Innovation Act (BPCIA) provides a stepwise approach for fact-finding prior to patent litigation, but companies may choose their own path, case examples show.  

The Inner Workings of the BPCIA Patent Dance

Without disclosing terms, Pfizer said it has settled with Johnson & Johnson (J&J) over a long-running dispute in which J&J was alleged to have blocked payers from covering Inflectra.

Pfizer Resolves Antitrust Lawsuit With J&J Over Remicade

Amgen's advertising appeared to push doctors and patients away from the prefilled syringe version of its pegfilgrastim (Neulasta) product, which may have a better sales future than the Onpro.

How Risky Was Amgen's Onpro Advertising? 

Panelists at the American Conference Institute's 2021 meeting took on the complexities of biosimilar adoption in a wide-ranging discussion.  

ACI Panelists Discuss Misaligned Incentives in the Biosimilars Market

Chad Landmon, JD, chair of Intellectual Property and FDA Practice at Axinn, Veltrop & Harkrider, provides a legal perspective on the implications of President Biden’s effort to improve the competitiveness of drug markets.

Axinn IP Chair Provides Analysis of Biden Biosimilars Initiative

Medicare lost out on over $2 billion in savings as adalimumab biosimilars were sidelined by patent restrictions, said investigators who recommended patent reforms.  

Study: Medicare's Lost Savings Due to Delayed Adalimumab Biosimilar Entry

Following the release of a whitepaper on sustainable generics and biosimilars markets, members of a trade association discussed concerning trends for the industry. 

Panel Discusses Generic, Biosimilar Marketplace Sustainability

The Center for Biosimilars® provided news and insight during June 2021 in the form of interviews with key opinion leaders and coverage of major events. Catch up on what you missed.  

Legal